Synairgen to Test SNG001 in Trial for COPD Exacerbations Caused by Viruses

Synairgen is moving from the treatment of respiratory viral infections in patients with asthma to those with chronic obstructive pulmonary disease (COPD) with its inhaled interferon beta investigative therapy SNG001. The pharmaceutical company is planning a two-part trial of SNG001 to treat viral infections in COPD patients to take place this…

COPD Study Indicates Certain White Blood Cells May Predict Patients’ Response to Inhaled Corticosteroids

Boehringer Ingelheim recently announced the publication of a new research article detailing the measurement of specific white blood cells, called eosinophils, to prediction the response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. The study was developed using data from the…